REPARE THERAPEUTICS INC (RPTX) Stock News
NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock - Currency: USD
RPTX Latest News, Press Relases and Analysis
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of 6.67% and 66.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CRVO
Exxon beats Wall Street profit estimate, on track to meet buyback target
HOUSTON (Reuters) -Exxon Mobil on Friday beat Wall Street's estimate for first-quarter profit as higher oil and gas production from Guyana and the Permian basin helped boost earnings. The buyback figure puts Exxon on track to meet its annual share repurchase goal of $20 billion. The energy sector has faced a tumultuous start to the year after U.S. President Donald Trump's global tariff announcements stoked recession fears.
Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks
Cardinal Health Inc. (NYSE:CAH) on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17. Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion. Adjusted operating earnings increased 21% to $807 million. Third-quarter sales for the Pharmaceutical and Specialty Solutions segment remained unchanged at $50.6 billion. Third-quarter revenue increased by 20%, excluding the impact of the customer contract expiration, dr
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
Repare Therapeutics Announces Leadership Transitions
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Why Is Repare Therapeutics Stock Trading Lower On Friday?
On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
